-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

Benzinga·03/11/2026 11:38:02
Listen to the news
Citizens analyst Reni Benjamin maintains Prelude Therapeutics (NASDAQ:PRLD) with a Market Outperform and raises the price target from $3 to $6.